Clascoterone Dosage Guide: Protocols, Calculator & Safety

Beginner protocols — getting started with clascoterone responsibly:

Prerequisite — dermatologic evaluation and appropriate indication: Clascoterone is a prescription medication (Rx-only) in the US and most jurisdictions; legitimate use requires physician prescription, typically from a dermatologist or primary care clinician experienced in acne management. Before starting, confirm: (1) diagnosis of acne vulgaris — not rosacea, folliculitis, perioral dermatitis, or other mimickers; (2) severity assessment — mild-moderate acne is typical candidate; severe nodulocystic acne may warrant isotretinoin rather than topical-only therapy; (3) age appropriate — FDA-approved for 12+; use in younger patients is off-label with HPA monitoring considerations; (4) pregnancy status for women of childbearing age — discuss pregnancy intentions and contraception; avoid in pregnancy; (5) current skincare regimen review — identify products to continue, discontinue, or sequence with clascoterone.

Standard dosing — 1% cream twice daily: Apply a thin layer of clascoterone 1% cream (Winlevi) to affected areas of the face twice daily — typically morning and evening — to clean, dry skin. The standard tube size is 60 grams, providing approximately 30 days of use at typical application quantities. Application amount: a pea-sized quantity to fingertips, spread across the affected face region (forehead, cheeks, chin, nose as needed). Do not over-apply; thicker applications do not improve efficacy and increase systemic absorption potential.

Application technique — beginner-friendly protocol:

1. Wash face with gentle, non-irritating cleanser — avoid harsh exfoliants, scrubs, or high-strength alpha-hydroxy/beta-hydroxy acid washes that can compound irritation.
2. Pat skin dry — do not rub; gentle pat with clean towel.
3. Wait a few minutes — particularly if freshly washed, allow skin to return to neutral dry state before applying clascoterone.
4. Apply pea-sized amount of clascoterone cream to fingertips.
5. Spread in thin layer across affected areas — forehead, cheeks, chin, nose as needed; avoid lips, eye area, broken skin.
6. Massage gently until absorbed — typically 5-10 minutes for full absorption.
7. Follow with moisturizer if desired — fragrance-free, non-comedogenic options (CeraVe, Cetaphil, La Roche-Posay Toleriane, similar); wait for clascoterone to absorb first.
8. Apply sunscreen in morning (SPF 30+ mineral or chemical, non-comedogenic) — general skincare best practice, not specifically mandated by clascoterone but always recommended.
9. Repeat at evening application with same sequence.

Trial duration — 12 weeks for initial efficacy assessment: Clascoterone efficacy builds over 4-12 weeks of consistent twice-daily use. Do not expect dramatic early improvement; clinical trial data show progressive lesion reduction throughout the 12-week evaluation period. Assessment checkpoints:

• Week 4: initial tolerability assessment; some patients may notice early improvement; if significant irritation, dose-adjustment strategies apply.
• Week 8: mid-course check; gradual improvement typically evident; continue if tolerating well.
• Week 12: primary efficacy assessment point; IGA improvement, lesion count reduction, overall patient satisfaction should be evaluated; continue if benefit achieved, consider escalation/combination/alternative if inadequate.

Tracking — beginner-level simplicity: (1) baseline photos of affected areas (standardized lighting, distance, angle); (2) note count of inflammatory and non-inflammatory lesions at baseline; (3) repeat at weeks 4, 8, 12; (4) patient-reported satisfaction and quality-of-life impact; (5) any tolerability concerns (application site reactions, general skin response).

Adjunctive foundational skincare: (1) Gentle, fragrance-free cleanser — twice daily; (2) Non-comedogenic moisturizer — daily, after clascoterone absorption; (3) Daily sunscreen — SPF 30+; (4) Avoid picking or squeezing lesions — increases scarring and inflammation risk; (5) Avoid known acne-triggering cosmetics — non-comedogenic makeup, minimize heavy occlusive products.

Managing initial irritation: If application site erythema, dryness, or mild irritation occurs in the first 1-2 weeks (happens in ~2-4% of patients):

• Reduce to once-daily application for 1-2 weeks, then build back to twice-daily as tolerated.
• Apply moisturizer more generously after absorption.
• Use gentler cleanser — discontinue any irritating astringents, exfoliants temporarily.
• Consider co-application pattern adjustment if also using retinoid or BP — space apart, alternate days.
• Persistent or severe irritation — contact prescriber; may need alternative agent.

Starting alone vs starting combined regimen: Clinical practice varies. Some dermatologists start clascoterone alone to establish tolerability, then add retinoid or BP after 2-4 weeks; others start combined regimens immediately in patients with moderate-severe acne. Beginner recommendation: starting clascoterone alone for first 2-4 weeks simplifies tolerability assessment and attribution of any skin reactions; add retinoid/BP subsequently once clascoterone is well-tolerated.

When to escalate to intermediate protocol: After 8-12 weeks of consistent monotherapy with partial but incomplete improvement — add retinoid and/or BP for combined regimen. Or if moderate-severe baseline severity with significant inflammatory component warrants immediate combination approach. Communicate with prescribing clinician.

Common beginner mistakes to avoid: (1) Applying too thickly — pea-size is sufficient for most faces; more cream does not improve efficacy; (2) Skipping doses — clascoterone requires steady-state exposure; inconsistent use reduces effect; (3) Expecting overnight results — acne pharmacology is gradual; full effects take 8-12 weeks; (4) Aggressive concurrent exfoliation — can compound irritation; keep regimen gentle; (5) Comparing to rapid-onset therapies — unlike BP (works in days on active C. acnes) or antibiotics (anti-inflammatory effects in 1-2 weeks), clascoterone's androgen-pathway mechanism takes weeks to months.

Intermediate protocols — expanded clascoterone regimens for moderate-to-severe acne:

Standard intermediate combination — Clascoterone + Topical Retinoid: Clascoterone 1% cream morning and evening + tretinoin 0.025-0.05% cream at bedtime (or adapalene 0.1-0.3% gel, or trifarotene 0.005% cream). Application schedule: morning — wash, apply clascoterone, allow absorption, moisturize, sunscreen. Evening — wash, apply clascoterone, allow 15-30 minutes absorption, apply retinoid to clean dry skin, moisturize as needed. Alternative schedule: morning clascoterone only (simplify timing); evening retinoid only (no concurrent clascoterone and retinoid). Efficacy may be slightly reduced with once-daily clascoterone but tolerability may be improved. Duration: 12-16 weeks for full efficacy assessment; many patients experience gradual improvement throughout this period. Monitoring: lesion counts, IGA assessment, patient satisfaction, tolerability. Photo documentation recommended for clearer change assessment.

Clascoterone + Benzoyl Peroxide: Clascoterone 1% cream morning and evening + benzoyl-peroxide 2.5-5% wash or leave-on gel once daily (typically morning). Application sequence: morning — BP wash or gel, rinse (if wash) and dry; apply clascoterone; moisturize and sunscreen. Evening — clascoterone + moisturizer. Addresses sebocyte androgens (clascoterone) and C. acnes (BP) simultaneously. Caveats: BP bleaches fabrics; combined application may cause more irritation than either alone; consider every-other-day BP initially if irritation.

Clascoterone + Retinoid + Benzoyl Peroxide (triple topical for moderate acne): Clascoterone morning + BP morning (separate, one after the other with waiting) + retinoid evening + clascoterone evening. Comprehensive topical regimen targeting all three non-microbial pillars of acne pathogenesis. Timing strategy: morning BP wash → dry → clascoterone → moisturizer → sunscreen. Evening → gentle cleanse → clascoterone → 15-30 min absorption → retinoid → moisturizer. Appropriate population: moderate acne not responding to two-agent combinations; patients with tolerance for combined regimen complexity. Caveats: increased irritation potential; adherence more demanding; cost considerations for multiple prescription products.

Clascoterone + Oral Antibiotic (short-course bridging): Clascoterone 1% cream twice daily + doxycycline 50-100 mg once or twice daily (or minocycline 50-100 mg daily) for 8-12 weeks. Provides rapid inflammatory reduction via oral antibiotic while topical regimen builds effect. After antibiotic course, continue topical regimen long-term. Appropriate population: inflammatory acne with significant papulopustular component needing rapid control; severe initial presentation; bridging therapy for patients awaiting dermatologist appointment. Caveats: antibiotic stewardship (avoid prolonged use > 3-4 months); photosensitivity (tetracyclines, especially doxycycline); GI effects; yeast infections; consider BP co-administration to reduce resistance risk.

Clascoterone + Systemic Spironolactone (adult women with hormonal acne): Clascoterone 1% cream twice daily + spironolactone 50-100 mg oral daily (sometimes escalated to 150-200 mg if needed). For adult women with moderate-to-severe hormonal acne. Systemic spironolactone provides oral AR antagonism + 5α-reductase inhibition, with known side effects (hyperkalemia, menstrual irregularity, breast tenderness). Clascoterone adds local sebocyte AR blockade. Monitoring: potassium at baseline and 4-6 weeks after initiation/dose change; blood pressure; menstrual cycle changes. Appropriate population: women 18+ with hormonal acne (cyclical, jawline, PCOS features). Duration: longer-term use typical (months to years).

Clascoterone + Combined OCP (adult women): Clascoterone 1% cream twice daily + combined OCP with acne-appropriate progestin (drospirenone/ethinyl estradiol, norgestimate/EE, norethindrone acetate/EE). Hormonal acne often responds well to estrogen-progestin combined OCP that reduces ovarian androgen production and increases SHBG. Topical clascoterone adds local AR blockade. Appropriate population: women of reproductive age with hormonal acne who need contraception; women with PCOS or other androgen excess conditions. Caveats: OCP risks (cardiovascular, thromboembolic); alternative contraception considerations for higher-risk patients.

Clascoterone + Topical Dapsone: Clascoterone 1% cream twice daily + dapsone 5-7.5% gel twice daily (to different areas or alternating). For moderate inflammatory acne with a prominent inflammatory component. Dapsone addresses inflammation and has mild antimicrobial action; clascoterone addresses sebogenesis. Tolerability: generally good combination.

Upper intermediate combination (strongly inflammatory or hormonal acne): Clascoterone + systemic antibiotic + topical retinoid + benzoyl peroxide — or — clascoterone + spironolactone + OCP + topical retinoid. Intensive multi-modal approach for moderate-to-severe acne not responding to two-agent combinations. Typically requires dermatologist coordination and close follow-up. Duration: 3-6 months for full assessment; many patients transition back to simpler maintenance regimens after initial intensive course.

Monitoring at intermediate level: (1) formal acne assessment — IGA at baseline, 4 weeks, 12 weeks; lesion counts; (2) tolerability — application site reactions, systemic effects if on oral meds; (3) specific lab monitoring based on regimen — potassium on spironolactone, LFTs on oral antibiotics long-term, HPA axis consideration with extensive topical regimens; (4) photo documentation — standardized photos to objectively track change; (5) quality-of-life / satisfaction — patient-reported improvement in acne impact on daily life; (6) adherence assessment — is the regimen feasible for the patient's lifestyle?

Treatment escalation framework at intermediate level: If intermediate-level combination therapy is inadequate after 12-16 weeks: (1) intensify regimen — add/upgrade components (e.g., add BP if not already using, escalate retinoid strength); (2) consider systemic escalation — oral spironolactone (women), systemic antibiotics, or ultimately isotretinoin; (3) hormonal workup — PCOS evaluation, testosterone/DHEA-S labs if features of androgen excess; (4) dermatologist consultation — if not already involved or if considering systemic therapy; (5) differential reconsideration — is the diagnosis correct? Consider folliculitis, perioral dermatitis, rosacea, cutaneous mycobacterial or deep fungal infections in resistant cases.

Cycling or drug holidays — not typically used: Unlike some compounds where cycling is recommended, clascoterone is used continuously for sustained acne control. Discontinuing can lead to flare recurrence (similar to discontinuing any chronic acne therapy). Reassessment at 6-12 months of ongoing benefit is reasonable; continuation as long as beneficial and tolerated.

Cost-benefit at intermediate level: Clascoterone (Winlevi) in the US typically costs ~$500-700 per 60g tube at retail without insurance; manufacturer savings programs and insurance coverage can reduce patient cost substantially. Combined with other topical/oral therapies and ongoing dermatologist visits, moderate acne management can cost $50-200+/month out-of-pocket depending on insurance and pharmacy. Compared to the psychosocial impact of poorly-controlled acne and to the cost of isotretinoin therapy (similar range per month plus monitoring labs), clascoterone-containing regimens are in the middle cost tier for modern acne therapy.

Transition strategies: (1) Maintenance after severe acne course — clascoterone is reasonable for maintenance after isotretinoin or aggressive treatment course; (2) Step-down after combination therapy — if acne well-controlled for 6+ months on combined regimen, consider simplifying (e.g., drop oral antibiotic, keep topical combination); (3) Scaling with life changes — women considering pregnancy: transition off clascoterone and spironolactone; plan with prescriber.

When to reassess: Every 6-12 months while on ongoing therapy. Does the current regimen still provide adequate acne control? Tolerability maintained? New considerations (pregnancy plans, cost concerns, regimen fatigue)? Is the diagnosis still accurate (occasionally adult acne is driven by medication, hormonal condition, or other modifiable factors)? Regular reassessment supports ongoing treatment optimization.

Advanced protocols and special contexts for clascoterone use:

Off-label hair loss protocols — the Mazzetti-derived approach and beyond: The primary off-label advanced application of clascoterone is topical treatment of androgenetic alopecia (male pattern and female pattern hair loss). Important framing: this is off-label use; clascoterone is not FDA-approved for hair loss; the evidence is preliminary (Mazzetti 2020 pilot, ongoing Breezula Phase 2/3); obtaining clascoterone for alopecia typically requires compounding pharmacy preparation or research protocol participation.

Basic hair loss stack — Clascoterone + Minoxidil (primary combination): Compounded clascoterone solution 5-7.5% applied twice daily to affected scalp + minoxidil 5% solution or foam twice daily to same areas. Application sequence: apply minoxidil first, allow absorption (ideally 4 hours, minimum 30 minutes), then apply clascoterone; or vice versa; or in some compounded preparations combined in single vehicle. Rationale: complementary mechanisms — minoxidil extends anagen and increases hair shaft diameter via vasodilatory/follicle mechanisms; clascoterone blocks DHT action at dermal papilla AR. Duration: 6-12 months for meaningful efficacy assessment; hair cycle biology dictates slow response. Monitoring: standardized hair count photos at baseline, 3, 6, 12 months; scalp tolerance; shedding patterns (expected transient shedding in first 4-8 weeks on new therapy).

Advanced hair loss stack — Clascoterone + Minoxidil + Finasteride: Topical clascoterone 5-7.5% twice daily + minoxidil 5% twice daily + finasteride 1 mg oral daily (men). Triple-mechanism approach: local AR blockade (clascoterone) + follicle stimulation (minoxidil) + systemic DHT suppression (finasteride). Rationale: comprehensive attack on androgenetic alopecia pathogenesis. Caveats: finasteride's sexual dysfunction risk (ED, reduced libido, reduced ejaculate) and post-finasteride syndrome concerns are not mitigated by adding clascoterone; alternatives include oral low-dose finasteride, topical finasteride, or dutasteride; women of childbearing age should not handle finasteride. Appropriate population: men with moderate-severe androgenetic alopecia seeking maximum medical therapy.

Intensive hair loss stack — Clascoterone + Minoxidil + Dutasteride: Topical clascoterone 5-7.5% twice daily + minoxidil 5% twice daily + dutasteride 0.5 mg oral daily or topical dutasteride 0.1%. Substitutes dutasteride (dual 5α-reductase inhibitor, more potent DHT reduction) for finasteride. Rationale: most potent systemic DHT suppression available. Caveats: larger side effect profile than finasteride; more pronounced sexual effects in some men; less reversibility concerns.

Female pattern hair loss adaptation: Topical clascoterone 5% twice daily + topical minoxidil 5% twice daily (women). Females with pattern hair loss often respond to topical therapies; systemic antiandrogens are used in specific contexts (spironolactone for women with associated hormonal features) but are not universally appropriate. Clascoterone's topical mechanism is attractive for women because it avoids systemic feminization/hormonal concerns and teratogenicity concerns of systemic 5α-reductase inhibitors. Caveats: off-label; compounded preparations; evidence is preliminary.

Clascoterone + topical finasteride (emerging combination): Topical clascoterone 5% twice daily + topical finasteride 0.25% twice daily. Dual topical mechanism targeting both DHT production (topical finasteride) and AR action (clascoterone) at the follicle, with reduced systemic exposure compared to oral finasteride. Caveats: both preparations are typically compounded; evidence for combined use is primarily inferential; regulatory status of topical finasteride varies by jurisdiction.

Maximal acne regimens — severe acne management with clascoterone inclusion: For severe acne not responding to standard combination therapies, intensive regimens may include clascoterone as one component of multi-agent therapy:

• Comprehensive severe acne regimen: clascoterone 1% cream twice daily + benzoyl-peroxide 5-10% + tretinoin 0.05-0.1% cream or gel + oral doxycycline 100 mg twice daily + spironolactone 100 mg daily (women) for 3-6 months, followed by step-down to maintenance.
• Pre-isotretinoin optimization: some dermatologists trial intensive topical regimens including clascoterone before committing to isotretinoin for severe acne; this approach is individualized and varies by clinician preference.
• Post-isotretinoin maintenance: after completing isotretinoin course, clascoterone is a reasonable choice for maintenance in patients at risk of relapse, particularly those with persistent androgen-driven features; combine with gentle topical retinoid for comedogenesis prevention.

Special populations — advanced considerations:

Adult women with PCOS or hyperandrogenism: Comprehensive dermatologic management often includes clascoterone as part of multi-modal approach: clascoterone topical + spironolactone + combined OCP + possibly topical retinoid + address underlying metabolic/endocrine contributions (insulin sensitivity, weight management, underlying PCOS workup). Dermatology-endocrinology coordination may be valuable.

Transgender patients: Clascoterone may have specific relevance for transgender men (female-assigned at birth) who develop acne during testosterone hormone therapy initiation. Clascoterone's topical mechanism provides acne-specific antiandrogen effect without interfering with the systemic gender-affirming hormonal regimen. Discussion with gender-affirming care team and dermatology.

Adolescents with moderate-severe acne: Clascoterone (age 12+) is appropriate; HPA axis monitoring considerations for younger adolescents (under 15) with extensive use. Typical adolescent regimen: clascoterone + topical retinoid + BP, with step-up to oral antibiotics or isotretinoin if inadequate.

Pregnant patients with acne: Clascoterone is NOT appropriate in pregnancy due to insufficient safety data. Alternatives: azelaic acid topical (category B), erythromycin topical (relatively safer), gentle cleansing, cosmetic coverage, and patience until postpartum when aggressive therapy can resume.

Breastfeeding patients with acne: Similar caution as pregnancy; prefer alternatives with better safety data; small-area clascoterone use may be acceptable in some contexts but should involve the patient's dermatologist and pediatrician.

Advanced monitoring considerations:

• Comprehensive dermatology follow-up every 3-6 months during active therapy.
• Photo documentation — standardized lighting, distance, angles; digital archive for longitudinal comparison.
• Lab monitoring based on systemic regimen components — potassium on spironolactone, LFTs on oral antibiotics, complete blood count and liver function on isotretinoin, testosterone if monitoring hormonal features.
• HPA axis consideration — periodic consideration of testing (morning cortisol, ACTH stim test) in patients with large-surface-area or prolonged intensive use, particularly pediatric patients.
• Outcome measures — IGA, lesion counts, hair counts (for alopecia), patient-reported quality of life.

Long-term clascoterone use considerations: The clinical safety database includes up to 12 months of continuous use (open-label extension). Use beyond 12-24 months is based on extrapolation and ongoing clinical experience rather than rigorous long-term trial data. Reassessment at 12 months should address: ongoing benefit, tolerability, consideration of stepping down or simplifying regimen, emerging alternative therapies. Most acne patients eventually step down to maintenance regimens (often topical retinoid with clascoterone or without) after extended periods of successful control.

Honest advanced-level framing: Clascoterone at the advanced level — whether in intensive acne regimens or off-label hair loss protocols — represents a genuinely useful pharmaceutical option with real but modest evidence base. It is not a miracle compound; it is a novel topical antiandrogen with meaningful but not dramatic efficacy, excellent tolerability at standard doses, and specific monitoring considerations (HPA axis in pediatrics, pregnancy avoidance). Advanced users should: (1) maintain dermatologist-coordinated care rather than self-directed intensive regimens; (2) understand the evidence tier — FDA-approved for acne (strong), off-label for hair loss (preliminary); (3) monitor appropriately — tolerability, efficacy, HPA considerations; (4) recognize alternatives — isotretinoin for severe acne, established minoxidil+finasteride for AGA, systemic antiandrogens for hormonal contexts — clascoterone does not categorically replace these options; (5) be prepared to de-escalate or switch if response is inadequate. Clascoterone expands the therapeutic armamentarium for androgen-influenced cutaneous conditions; it is not a standalone solution for all such conditions.